Trial Profile
A Phase IIa, Randomised, Parallel, Double-Blind,Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MEDI0382 in Japanese Preobese or Obese Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Dec 2021
Price :
$35
*
At a glance
- Drugs Cotadutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca
- 01 Aug 2021 Results assessing the safety and pharmacokinetics of cotadutide in phase 1 (n=32; 24 Japanese and 8 Chinese healthy adults) and phase 2 (n=61 Japanese adults) trials in overweight or obese participants of Asian descent with or without type 2 diabetes, published in the Diabetes, Obesity and Metabolism.
- 29 Jan 2019 Status changed from active, no longer recruiting to completed.
- 20 Dec 2018 Planned End Date changed from 6 Dec 2018 to 23 Jan 2019.